-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Novartis announced today that Pataday (common name: 0.2% hydrochloric acid olotatin eye drops) has been approved by China's State Drug Administration (NMPA) for the treatment of allergic conjunctivitis-related itching.
, according to a press release, Pataday is an upgraded version of olotta hydrochloride.
It increased the concentration of olotatin hydrochloric acid to 0.2%, not only continue to maintain the dual-effect anti-sensitivity mechanism, but also reduce the frequency of use, once a day, can be 24 hours long-lasting and effective, for China's allergic conjunctivitis patients have brought more convenient treatment options.
dual-acting drugs are the preferred basic drug for the treatment of allergic conjunctivitis, olotatin hydrochloric acid as a typical two-acting drug with antagonist and stable hypertrophic cell membrane, through two mechanisms can effectively suppress the symptoms and signs of patients with allergic conjunctivitis, has been recommended by China's domestic and foreign guidelines as a first-line treatment drug.
Professor Shi Weiyun, director of The Eye Hospital of Shandong Province and head of the corneal disease group of the Ophthalmology Branch of the Chinese Medical Association, said: "0.2% hydrochloric acid olotatin eye drops are iteratively updated allergic conjunctivitis treatment drugs, providing a more convenient way to treat patients with allergic conjunctivitis.
Pataday as an upgraded version of olotatad eye drops hydrochloric acid, while continuing to maintain dual-acting anti-sensitivity, will also use the frequency of reduction, is conducive to improving treatment compliance, and further standardize the management of patient self-medication.
" allergic conjunctivitis refers to a common eye disease caused by immune disorders that causes inflammatory reactions to the conjunctivitis, with an occurrence rate of 6% to 30% in the general population and up to 30% in children.
its most classic performance is after the onset of the eye will be sharp itching, and even will feel the eye burning accompanied by water-like secretions, conjunctivation redness, eyelids will also swell, seriously affecting normal life.
if the treatment is not timely, later with the progression of the disease, and even affect visual effects or cause visual impairment, so for allergic conjunctivitis, early detection, timely treatment is very important.
, president of Novartis China, said Pataday's approval has opened up new and more convenient and effective treatment options for patients with allergic conjunctivitis in China.
will work with a number of parties to make Pataday more access to Chinese patients faster.
。